Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/102836
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGalougahi, K.-
dc.contributor.authorAntoniades, C.-
dc.contributor.authorNicholls, S.-
dc.contributor.authorChannon, K.-
dc.contributor.authorFigtree, G.-
dc.date.issued2015-
dc.identifier.citationEuropean Heart Journal, 2015; 36(25):1576-1582-
dc.identifier.issn0195-668X-
dc.identifier.issn1522-9645-
dc.identifier.urihttp://hdl.handle.net/2440/102836-
dc.description.abstractThe central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application. However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.-
dc.description.statementofresponsibilityKeyvan Karimi Galougahi, Charalambos Antoniades, Stephen J. Nicholls, Keith M. Channon and Gemma A. Figtree-
dc.language.isoen-
dc.publisherOxford University Press-
dc.rights© The Author 2015.-
dc.subjectRedox signalling; Biomarker; Cardiovascular disease; Reactive oxygen species; Caveolae-
dc.titleRedox biomarkers in cardiovascularmedicine-
dc.typeJournal article-
dc.identifier.doi10.1093/eurheartj/ehv126-
dc.relation.grantNHMRC-
pubs.publication-statusPublished-
dc.identifier.orcidNicholls, S. [0000-0002-9668-4368]-
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.